
Network News

The European vaccine development ecosystem has been strengthened over the last 16 years, thanks to the EVI-led TRANSVAC project, an ambitious initiative funded by the European Commission. Since its launch in 2009, TRANSVAC has established itself as a key player in advancing vaccine research, supporting over 160 vaccine projects while fostering innovation and collaboration in […]
read more
Akribion Therapeutics exits from stealth with €8m seed financing to pioneer RNA-guided, programmable cell depletion
Zwingenberg, Germany, 4 February 2025 – Akribion Therapeutics (“Akribion”), the early-stage biotech developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announces its exit from stealth and the completion of a Seed Financing round raising EUR 8 million to accelerate the development of novel therapeutics based on Akribion’s proprietary G-dase® E nucleases. The round […]
read more
Gyros Protein Technologies introduces Gyrolab HEK293 HCP Type SN and Type CL Kit Reagents to support biotherapeutic development
Uppsala, Sweden, 05 February 2025: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers, today announced the introduction of its Gyrolab® HEK293 HCP Type SN Kit Reagents and Gyrolab HEK293 HCP Type CL Kit Reagents. Developed with antibodies from BioGenes GmbH, a global leader in host cell protein (HCP) assay […]
read more
BioMed X Institute and Merck Successfully Complete Extrachromosomal DNA in Cancer Research Project
The research of BioMed X team EDC – Extrachromosomal DNA in Cancer – has uncovered critical insights into the mechanisms driving extrachromosomal DNA (ecDNA) formation and maintenance, offering potential avenues for novel cancer therapies. Heidelberg, Germany, February 6, 2025. BioMed X, a German independent research institute, announces the successful completion of its oncology research project in partnership […]
read more
EU-OPENSCREEN announces new service category: Chemoproteomics and Spatial MS-Based Omics
Three institutions have joined our consortium as official Chemoproteomics and Spatial Mass Spectrometry (MS)-Based Omics partner sites, enhancing the services we can offer to the research community in the areas of target identification and validation. Phil Gribbon, Director General of EU-OPENSCREEN, emphasised: “The three new chemoproteomics sites joining the EU-OPENSCREEN partner network provide a significant boost […]
read more
YUMAB and InSCREENeX are developing an innovative “Mammalian Display” screening platform to accelerate antibody development.
Braunschweig, January 29th, 2025 – YUMAB GmbH, a German biotechnology company specializing in contract research for therapeutic antibodies, announces its collaboration with InSCREENeX GmbH to establish a novel technology for antibody development. As part of the funded project “Mammalian Display,” the two Braunschweig-based companies are developing a platform that enables the screening of antibody libraries […]
read more
New weapons against viruses
Dr. Petr Chlanda, virologist and research group leader at the Heidelberg Medical Faculty of Heidelberg University, has been awarded more than 720,000 euros in funding from the European Union for his research into new therapies against viruses. His work is part of the interdisciplinary, international DEFENDER project, which is developing innovative approaches to combat emerging […]
read more
BlueRock Therapeutics advances investigational cell therapy bemdaneprocel for treating Parkinson’s disease to registrational Phase III clinical trial
Phase III exPDite-2 trial follows completion and discussion of Phase I trial data with US FDA under Regenerative Medicine Advanced Therapy (RMAT) designation / exPDite-2 is a randomized, sham surgery-controlled double-blind trial assessing efficacy and safety of bemdaneprocel in people living with moderate Parkinson’s disease / Expected to be initiated in H1 2025, exPDite-2 is […]
read more
BioMed X Institute Launches New Collaboration with Daiichi Sankyo in Cancer Therapy
Heidelberg, Germany, January 14, 2025. BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new collaboration with Daiichi Sankyo Co., Ltd., a global pharmaceutical company headquartered in Japan. This collaboration marks the start of a cutting-edge initiative to explore innovative approaches in cancer treatment using multi-specific biologics. The new […]
read more